Anima Biotech is advancing Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against many diseases. With novel biology that monitors the translation of proteins and proprietary cloud-based software, we identify drug candidates that modulate a target protein’s production. We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Our approach was further validated with 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Collagen I translation inhibitors
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):